2 Tower Pl, Suite 800
South San Francisco
Tel: (650) 825-6140
About Pionyr Immunotherapeutics
Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.
The company was founded in 2015 by Max Krummel, Ph.D., a professor at University of California, San Francisco School of Medicine (UCSF), who has been making significant strides in immuno-oncology since the mid-1990s. Dr. Krummel is the co-inventor of YERVOY® (ipilimumab), the first checkpoint inhibitor, which was approved in 2011 to treat melanoma. Pionyr has exclusively licensed technology from UCSF based on Dr. Krummel’s work.
Our employees are passionate about Pionyr’s mission: To develop innovative therapeutics that dramatically alter the tumor microenvironment thereby enabling the human immune system to successfully fight and, potentially, eliminate cancer. We offer an environment where individuals make a difference and have a voice. At Pionyr, communication is open and transparent, teams are empowered, and quality and integrity are paramount.
We greatly value our employees, and this is reflected in the comprehensive and above market compensation and benefits packages we provide to support the health and well-being of our “Pionyrs” and their families.
Join us and become an integral part of a leading immune-oncology company where you will have a direct impact on our research and clinical programs and have an opportunity to learn from proven, experienced scientific and business leaders. We look forward to hearing from you.
13 articles with Pionyr Immunotherapeutics
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement
Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced that Pionyr and Gilead Sciences, Inc. have mutually agreed to change their 2020 exclusive option agreements.
Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022
Pionyr Immunotherapeutics, Inc. will present pre-clinical data showing the potential for its PY265 program to treat solid tumors, as a single agent and in combination with checkpoint inhibitor (CPI) therapy.
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY159
Pionyr Immunotherapeutics, Inc announced it has begun dosing patients in its Phase 1b expansion study investigating PY159 in patients with prioritized cancer types: ovarian cancer, pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), HR+HER2- breast cancer, head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC).
Pionyr Immunotherapeutics to Present on Myeloid Tuning Platform and TREM1 Targeting Antibody Program at the Tumor Myeloid-Directed Therapies Summit
Presentation by Pionyr Chief Medical Officer Leonard Reyno, M.D., features leading research in modulating innate immunity to treat cancer.
Pionyr Immunotherapeutics’ Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022
Pionyr Immunotherapeutics, Inc., announced today that PY314, a monoclonal antibody targeting TREM2 (triggering receptor expressed on macrophages 2), was safe and well-tolerated in a Phase 1a dose-escalation study as a single agent and in combination with pembrolizumab at its label-approved dose.
Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board
Pionyr Immunotherapeutics, Inc. announced today that Johanna Joyce, Ph.D., Olivier Elemento, Ph.D., and Michael Quigley, Ph.D., will join Miriam Merad, Ph.D., as members of Pionyr’s Scientific Advisory Board.
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314
Pionyr Immunotherapeutics, Inc. announced that the first patient has been dosed in Phase 1b expansion studies investigating PY314 in patients with solid tumors.
Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development
The collaboration with Pionyr Therapeutics demonstrates Lonza’s flexibility to tailor its offering to accommodate the specific needs of our customers. Our team has created a cell line development program relying on a state-of-the-art platform technology that brings a faster and streamlined approach to selecting an ideal cell line.
PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study Of PY314
Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's antitumor immunity by altering the composition and function
Today, Gilead announced that it was acquiring a 49.9% equity interest in Pionyr Immunotherapeutics for $275 million and exclusive option to buy the rest of the company.
PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
PIONYR Immunotherapeutics, Inc. announced the appointment of Alicia Levey, Ph.D., as Senior Vice President and Chief Business Officer.
ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-oncology Contract Development and Manufacturing Project
ProBioGen AG and Pionyr Immunotherapeutics, today announced a second service and license agreement to develop novel antibody therapeutics.
Pionyr was founded in 2015 by a UCSF professor and a Genentech alum.